Table 1 Clinical and biochemical characteristics of the study subjects (n = 179)
Variable | Latino (n = 119) | Non-Latino white (n = 60) | ||
|---|---|---|---|---|
| Â | Men (n = 38) | Women (n = 81) | Men (n = 21) | Women (n = 39) |
Age, yr | 60.2 ± 10.2 | 60.6 ± 10.4 | 61.7 ± 9.6 | 63.9 ± 7.5 |
BMI, kg/m2 | 32.6 ± 5.4 | 33.0 ± 6.3 | 31.3 ± 8.0 | 34.7 ± 7.6 |
Waist Circumference, cm | 109.9 ± 13.7 a | 102.5 ± 15.4 | 112.0 ± 20.3 | 109.0 ± 16.0 c |
Type 2 Diabetes | 57.9% | 51.9% | 42.9% | 35.9% |
HOMA-IR | 5.3 (3.4-9.2) | 4.5 (3.0-6.5) | 4.1 (2.0-6.9) | 3.7 (2.3-5.6) |
Log(HOMA-IR) | 1.7 ± 0.7 | 1.4 ± 0.7 | 1.2 ± 1.2 | 1.2 ± 0.9 |
Fasting Insulin, μU/ml | 18 (12-26) | 17 (12-23) | 16 (8-25) | 16 (9-22) |
Estimated GFR, ml/min | 89.6 ± 30.7 | 90.7 ± 24.4 | 83.5 ± 22.0 | 74.9 ± 23.8 d |
Total Cholesterol, mg/dl | 171 ± 46.2 | 181 ± 36.6 | 182 ± 41.3 | 192 ± 41.3 |
Triglycerides, mg/dl | 162 (104-241) | 159 (120-204) | 135 (91-164) | 146 (108-207) |
LDL, mg/dl | 91.9 ± 35.6 | 95.3 ± 32.7 | 99.8 ± 32.8 | 103.3 ± 31.8 |
HDL, mg/dl | 43.4 ± 9.3 b | 53.0 ± 12.5 | 48.0 ± 12.4 | 55.1 ± 13.9 |
Systolic BP, mm Hg | 141 ± 19.4 | 144 ± 23.1 | 141 ± 24.1 | 139 ± 21.7 |
hs-CRP, mg/L | 2.8 (1.0-5.3) | 3.5 (1.7-6.5) | 1.8 (0.9-3.7) | 3.5 (1.2-8.5) |
ACEI or ARB use | 68.4% | 56.8% | 42.9% | 53.9% |
TZD use | 18.4% | 14.8% | 0% c | 7.7% |
ASA use | 26.3% | 30.9% | 57.1% c | 35.9% |
Statin use | 63.2% | 43.2% | 52.4% | 56.40% |
Total Adiponectin, μg/ml | 4.6 (3.8-6.5) b | 7.0 (4.9-11.4) | 6.0 (5.0-10.6) ac | 11.4 (7.3-17.1) d |
HMW Adiponectin*, μg/ml | 2.3 (1.2-3.7) a | 2.8 (1.7-5.0) | 2.9 (2.0-3.9) a | 4.4 (2.8-7.9) d |